Bruzzone, M <br/><br/>
Second-line treatment with intravenous gemcitabine and oral etoposide in platinum-resistant advanced ovarian cancer patients: results of a phase II study.  [electronic resource] 

 -  Oncology  2011 
 - 238-46 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>1423-0232 
<br/><br/><label>Standard No.: </label>10.1159/000328451  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>CA-125 Antigen--blood<br/>Deoxycytidine--administration & dosage<br/>Drug Resistance, Neoplasm<br/>Etoposide--administration & dosage<br/>Female<br/>Humans<br/>Middle Aged<br/>Ovarian Neoplasms--blood<br/>Platinum--therapeutic use<br/>Survival Analysis<br/>Treatment Outcome<br/>Gemcitabine